Randomised clinical trials on progression of renal diseases usually include patients according to criteria for blood pressure, renal function and proteinuria. There is no data showing that this provides groups with similar baseline rates of renal function loss. Accordingly, the impact of pre-intervention rate of renal function loss (slope) on outcome of studies has not been established.
GENE-ENVIRONMENT INTERACTION AND THERAPY RESPONSE TO ACE-INHIBITION

Part 1 Introduction
In chronic renal disease, renal function usually deteriorates progressively towards end stage renal failure. Major effort was made over the last decade to develop and evaluate renoprotective strategies by long term intervention studies in man [1] [2] [3] [4] [5] [6] [7] . Whereas the rate of renal function loss is usually fairly constant in time for individual patients, the degree of loss varies greatly between patients [8] .
Theoretically, for studies on progressive renal function loss it would be best to include or randomize patients according to their prior rate of renal function loss (pre-intervention slope). This could ensure an equal allocation of patients with high or low risk for progression to different treatment groups. Not surprisingly, such an approach has not been applied for comparative parallel trials, because of obvious practical problems in obtaining data on the rate of renal function loss before intervention. Therefore, patients are usually included according to baseline cross-sectional parameters, like renal function, blood pressure, and proteinuria as indirect indicators of renal prognosis.
We hypothesized that the prior rate of renal function loss might be the main determinant of progression during intervention and that accordingly, neglect of this information could bias the interpretation of the results of intervention. To test this hypothesis, we collected data on preintervention rate of renal function loss for individuals that had participated in a 4-year double blind randomized intervention trial. Previously, two analyses have been performed on this dataset. First, a double-blind randomised comparison of enalapril vs atenolol, that revealed no differences between the regimens on I-iothalamate measured glomerular filtration rate slope [9] . Second, a post-hoc analysis on the effect of ACE genotype that showed a faster progression rate in the DD subjects [10] .
In the current analysis we evaluated, first, whether pre-intervention slope was distributed equally over the groups. Second, we re-evaluated differences in treatment benefit, defined as slope improvement, in the comparison between enalapril and atenolol, and the comparison between the genotypes, respectively. Finally, we evaluated whether pre-intervention slope was a determinant of the slope during intervention.
Methods
Patients
In the previously published report, 89 patients with non-diabetic renal insufficiency were studied according to a prospective parallel randomized double-blind design [10] . In short, four weeks after withdrawal of antihypertensive drugs, baseline measurements were obtained. Inclusion criteria were a creatinine clearance of 30 to 90 ml/min, 18 to 65 years old, and a diastolic blood pressure of more than 80 mmHg. Patients were stratified according to baseline creatinine clearance (either 30 to 60 or 60 to 90 ml/min) and afterwards randomized to treatment with atenolol or enalapril (starting dose 50/10 mg o.i.d. respectively). Drug dose was titrated on a goal diastolic blood pressure of 10 mmHg below baseline and/or below 95 mmHg. Patients were followed for three to four years (mean 189 weeks).
Pre-intervention slope and benefit of intervention
At each visit, blood pressure was measured (during baseline and during the intervention period by automated device, Dinamap®), 24 hour urine was collected for determination of proteinuria (by pyrogallol red molybdate method) and creatinine. Blood was drawn for creatinine measurement (by standard autoanalyzer, SMA-C, Technicon®) to calculate creatinine clearance. Values were corrected for body surface area (1.73 m2). ACE genotype was determined by PCR method using two different specific insertion primers to confirm putative DD genotypes and prevent mistyping as previously described [11] . For the present analysis, data on the period before study entry (during regular patient care) were retrospectively collected from patient records. Subjects were included if at least one year of follow up during the pre-intervention period was available, with three or more data points for each parameter. ACE genotype was obtained in 81 patients. A total of 60 patients could be included in the present analysis. Polycystic kidney disease (n) 11 9 miscellaneous (n) 21 14 Data are expressed as mean ± SD and are given for the original study and for the patients in the present analysis.
Statistical Analyses
Data on creatinine clearance and blood pressure are given as mean ± SD and data for proteinuria as median and inter-quartile range during retrospective and prospective follow up. The blood pressure and antiproteinuric responses were analysed as the change from baseline, that is, four weeks after withdrawal of prior treatment. The baseline characteristics of the original and the present analysis study group were compared by Chi-square (Χ 2 ) test (gender, age, ACE genotype, treatment, and type of disease) and non-parametric Mann-Whitney U test (continuous variables). Differences between atenolol/enalapril and ACE genotype groups were tested for slope, blood pressure and proteinuria by non-parametric ANOVA test. Mann-Whitney test was used to detect differences between the subgroups. Progression of renal function loss was estimated for each individual by calculating the slope of creatinine clearance over time by the least squares regression method. The slope of renal function during the prospective study period is presented as the slope calculated from the data points as of three months onwards, to eliminate the influence of the initial effect of antihypertensive treatment on renal function [10] . The number of data points per individual available for slope calculation was 12 ± 6. The creatinine clearance slope during the intervention period corresponded to the 125I-iothalamate measured glomerular filtration rate slope, without systematical errors on the Bland and Altman
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Data are expressed as mean ± SD or median and quartile range* p<0.05 compared to other genotypes, # p<0.05 compared to baseline analysis. The mean differences and 95% limits of agreement were 0.02 (-2.5/2.5) for the slope measurement.
A paired non-parametric Wilcoxon test was used to test the differences between blood pressure, proteinuria, and slope between the pre-intervention and the intervention period. In addition, the determinants of the intervention slope were analysed by multiple regression analysis. For this purpose, intervention slope was modelled as outcome variable, with the pre-intervention slope, ACE genotype, and intervention slope. In these 15 patients the intervention slope was -4.7 ± 0.7 ml/min/yr. To analyse for the accuracy of pre-intervention slope, and the different baseline parameters as predictors for rapid progression, the area under the receiver operating characteristic (ROC) curve was calculated. This statistic may vary from 0 to 1, with 1 indicating perfect discrimination and 0.5 indicating a value expected by chance alone. A two-sided p-value less than 0.05 was considered to be significant.
Analyses were performed with SPSS version 14.0 (SPSS Inc., Chicago, IL) with the exception of ROC analysis, which was performed with AccuROC 2.5 (Accumetric Corporation, Montreal, Canada).
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Figure 1 | Creatinine clearance slopes (ml/min/yr/1.73 m2) for atenolol and enalapril (panel A) and for the genotypes (panel B) separately during the pre-intervention and the intervention period.
The pre-intervention slope is drawn by taking baseline renal function as reference and calculating renal function loss backwards. The intervention slope is calculated from three months on treatment to end of follow up. A significant improvement in slope was present in the enalapril group, which was absent in the atenolol group. A significant benefit of intervention was apparent from the improvement in rate of renal function loss only in the DD genotype. No such improvement was found in the other genotypes. * p<0.05 compared to atenolol, ** p<0.05 compared to other genotypes, # p<0.01 compared to pre-intervention period.
Results
A total of 60 patients could be included in the present analysis. During the pre-intervention period, mean follow-up was 59.2 ± 5.5 months. The other 21 patients all entered the prospective trial within one year after the diagnosis of renal disease. Therefore, in those patients the pre-intervention period was too short to allow a valid slope assessment. Baseline characteristics in the present study sample
were not significantly different from the original population (table 1) . Also, the characteristics of the patients not included were not different from those included. The groups randomized to enalapril or atenolol (table 2, left part) were not significantly different for baseline creatinine clearance, MAP and proteinuria. During intervention, in accordance with our previous report, MAP and proteinuria were similar during enalapril and atenolol [9] . During the pre-intervention period MAP and proteinuria were similar in the enalapril and atenolol groups. The rate of renal function loss (slope) was as well similar during intervention ( figure 1A) . However, the pre-intervention rate of renal function loss was higher in the enalapril group (p=0.05). As a consequence, when comparing the pre-intervention slopes with the intervention slopes, the enalapril group had a significant improvement of slope (p=0.018), which was absent in the atenolol group.
In the corresponding data for a division according to ACE genotype (table 2, right part), baseline creatinine clearance was higher in the II genotype, with similar MAP and proteinuria for the three genotypes. During intervention, in accordance with our previous report, MAP and proteinuria were similar for the genotypes, with a higher rate of renal function loss in DD homozygotes (figure 1B) [9] .
Remarkably, pre-intervention rate of renal function loss was significantly higher in the DD group than in the other genotype groups.
Consequently, in the group with the DD genotype, a significant benefit of intervention was apparent from the improvement in rate of renal loss during intervention (p=0.0012, figure 1 ). No such improvement was found in the other genotypes. On univariate analysis the pre-intervention slope was correlated to the intervention slope (R2=0.13, p=0.005). Baseline proteinuria was negatively correlated to the intervention slope (R2=-0.12, p=0.008). Baseline creatinine clearance and MAP did not correlate to the intervention slope.
On multivariate analysis the pre-intervention slope and pre-intervention proteinuria were both independent predictors of intervention slope ( However, when pre-intervention slope was included, the contribution of ACE genotype was no longer significant. The predictive value of baseline proteinuria for an intervention slope in the highest quartile was significant, shown by an area under the ROC of 0.65 ± 0.08 (p=0.04 vs. reference line). The predictive value of the pre-intervention slope was somewhat better 0.73 ± 0.07 (p=0.008 vs. reference
Pre-intervention slope and benefit of intervention line). When combining the pre-intervention slope and proteinuria, the predictive value for rapid progression was the highest, as shown by an area of 0.75 ± 0.07 (p=0.005 vs. reference line).
Discussion
This study shows that stratification over different therapy arms according to baseline creatinine does not guarantee equal distribution of prior rate of renal function loss, and that this may be relevant to study outcome. First, we found a difference in pre-intervention slope between the randomized groups. Second, the therapeutic benefit in terms of slope improvement did not correspond on a one-toone basis with the therapeutic outcome based on between-group comparison during treatment only.
Finally, the pre-intervention slope was an independent determinant of intervention slope, and consideration of pre-intervention slope improved the prediction of progression during the study.
We retrospectively investigated whether the stratification according to baseline creatinine clearance resulted in an equal distribution of renal function loss before intervention. The preintervention slopes were different between the two treatment arms, despite similar creatinine clearance, blood pressure and proteinuria at baseline. Therefore, taking into consideration preintervention slope could put the results of this study into a different perspective. We previously reported a similar rate of renal function loss with enalapril and atenolol [10] , and accordingly, could not detect a difference in renoprotective efficacy between the regimens. However, when expressed in terms of slope improvement the enalapril group had a clear slope improvement while this was absent in the atenolol group. As the intervention slopes were similar, the difference between the groups in terms of slope improvement appears to be related to the slightly higher prior rate of renal function loss in the enalapril group.
Usually, patients are selected and randomized for renal risk based on serum creatinine and proteinuria. By randomizing it is presumed to achieve an equal distribution of renal risk markers over the treatment arms. However, apparently, such an equal distribution is not always obtained: in the RENAAL study, for instance, there was a baseline difference in proteinuria which was calculated to affect its outcome [12] . Our data suggest that inclusion of data on pre-intervention rate of renal function decline may serve to obtain groups with a comparable renal risk during intervention, thus increasing the validity of the study. Table 3 
| Regression analysis of relation between proteinuria and pre-intervention slope and intervention slope
The impact of prior rate of renal function decline was even more remarkable for the analysis of the effect of ACE genotype on study outcome [9] . Assessed from parallel intervention data only, the steeper slope in the group with the DD genotype during intervention suggests lack of renoprotective benefit in these subjects. The pre-intervention data revealed, remarkably, that slope improvement was most pronounced in DD homozygotes, which sheds a different light on the nature of their responsiveness to therapy. This treatment benefit in DD subjects is in accord with other studies [13] [14] [15] and -according to our data -may be explained by their steeper pre-intervention slope rather than by ACE genotype as such, as slope improvement closely correlated with the pre-intervention rate of renal function decline independently of genotype. Several studies have reported on the slope in subjects with DD genotype, with conflicting results [9;13-19] . Recent data from the RENAAL study, published in abstract form, show that proteinuric type 2 diabetic patients with the D allele of the ACE gene have an unfavourable renal prognosis which can be mitigated by losartan treatment [20] . The RENAAL data are in line with our current results which show a steeper pre-intervention slope in patients with the DD genotype along with a better risk reduction during intervention. The parallel with our current data is remarkable, and taken together these data suggest that optimal treatment is even more important in patients with rapid progression associated with the D allele.
When designing intervention studies on renoprotection, a solid estimate of progression rate during the study is of major importance. Proteinuria is a consistent predictor of progression rate. In concordance, in the present analysis baseline proteinuria predicted 12% of the variability in Pre-intervention slope and benefit of intervention progression rate during the study. Interestingly, by including the pre-intervention slope the predictive power of the model doubled to 24%. Thus, knowledge of the pre-intervention slope allowed a better prediction of the slope during intervention. This suggests that it would be worthwhile to document prior rate of renal function loss of patients considered for intervention studies. In our study proteinuria and pre-intervention slope contributed equally to the model, but it should be mentioned that baseline proteinuria was fairly low in our study, and that the relative contributions of proteinuria and preintervention slope might have been different in populations with higher proteinuria.
Our data strongly suggest that taking into account pre-intervention slope during stratification allows a more valid comparison of treatment effects in the study arms. In our own study a possible difference between the two agents could have been missed by neglecting pre-intervention slope in the stratification. The predictive value of pre-intervention slope for the slope during intervention, a frequently used surrogate endpoint, is of clear relevance for future studies on renoprotective intervention. This holds particularly true for trials with relatively small numbers of patients, where inclusion of non-progressors may have a relatively large impact. Our data suggest that it would be fruitful to consider prior rate of renal function loss -if available-as stratification parameter as stratification on cross-sectional parameters may not warrant a sufficient match for the risk for renal function loss. This may substantially enhance the power to detect differences between treatment arms and thus reduce the required number of patients.
Our study has several limitations. Most importantly, the pre-intervention data in this study were obtained retrospectively. Therefore, the potential flaws of a post-hoc analysis and notably selection bias should be considered. From the original 81 patients, 21 could not be included. However, the only reason for non-inclusion of these patients was that the pre-intervention period was less than a yearprecluding accurate assessment of the pre-intervention slope. Therefore, no patients were lost to follow-up, and the intention to treat principle was not violated. Moreover, there were no significant differences between patients included in the current analysis and those not included. Thus, by lack of knowledge on pre-intervention slope in these 21 subjects we cannot exclude selection bias completely but we consider it unlikely that it plays a major role in the present results.
The implication of our study would be that renal intervention studies should include an assessment of pre-intervention data in the inclusion criteria. This will pose considerable practical challenges, but it is not entirely at variance with current practice. In several large trials the inclusion criteria include data on the course of pre-intervention renal function, usually to exclude patients with a very rapid rate of renal function loss [2;4;21] . The AIPRI trial for instance, included only patients with less than 30% variation in 24 h estimated creatinine clearance in a three-month screening period [2] . To assess the slope, pre-intervention data on a period longer than three months, i.e. at least a year with a minimum of three data points, would be necessary for all patients. This would increase the total observation Chapter 2
period, and, in newly identified patients, postpone the start of the intervention. Whereas this can be considered a disadvantage in view of the usual time pressure, it might be balanced by a greater power to detect intervention-associated differences between the groups. If no creatinine clearance data are available, a slope derived from the reciprocal of serum creatinine might serve the purpose. It should be emphasized that, if adopting this policy, pre-intervention data should be available in all patients, in order not to introduce a selection bias.
In conclusion, pre-intervention rate of renal function loss is a main determinant of future rate of renal function loss. Neglect of the prior rate of renal function loss may result in differences in risk for progression between treatment arms in randomized trials, thus confounding the outcome of studies on long term renoprotection. Considering prior rate of renal function loss as a randomization parameter, albeit cumbersome, may enhance study power and thus allow conducting valid studies in smaller numbers of patients.
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